ACT appointed to conduct Phase IIa trial of POLB 001

09/30/25

ACT appointed to conduct Phase IIa trial of POLB 001

...

Poolbeg granted FDA ODD for CRS cell therapy

05/28/25

Poolbeg granted FDA ODD for CRS cell therapy

...

CRS prevention: Taking the sting from CAR-T’s tail

04/28/25

CRS prevention: Taking the sting from CAR-T’s tail

...

Meet the Researcher: Liam Tremble

09/17/24

Meet the Researcher: Liam Tremble

...

The uncapped potential of cancer research (Page 39)

06/27/24

The uncapped potential of cancer research (Page 39)

...

Removing the needle: the unmet need for oral GLP-1 drugs

06/12/24

Removing the needle: the unmet need for oral GLP-1 drugs

...

Treatment potential for immunotherapy-induced CRS

01/18/24

Treatment potential for immunotherapy-induced CRS

...

AI-led programme identifies multiple influenza drug targets

06/30/23

AI-led programme identifies multiple influenza drug targets

...

SLAS2023: We have the building blocks, onto the building

02/13/23

SLAS2023: We have the building blocks, onto the building

...

Poolbeg Pharma
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.